Procept Biorobotics Corp: what the price is pricing in
The price implies an owner-earnings margin of 8.3%; the company has kept -49.6%. That gap is wide enough for a short position this quarter. Switch lens below to see the same question asked of earnings, growth, sales and book value.
No published rating for Procept Biorobotics Corp: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet. The readings below run our models backwards for research and show how trading the gap would have done; they are not a valuation or a rating. The valuation page shows the models and their status.
What profit margin is the price paying for?
The price implies an owner-earnings margin of 8.3%; the company has kept -49.6%.
Market more optimistic than our model: short this quarter
Over time
$10,000 trading the gap vs the S&P 500
Skill or luck?
In plain English: Across 14 quarters with a position, this lens beat the S&P 500 in 9, by +5.8% a quarter on average. That could easily be chance. One company is a small sample: the results across all companies are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 0 | — | — | — | — | — | — |
| Shorts | 14 | 64.3% | +5.8% | +7.9% | +16.4% | 1.05 | No reliable evidence |
| All positions | 14 | 64.3% | +5.8% | +7.9% | +16.4% | 1.05 | No reliable evidence |
Every quarter (15)
| From | Price paid | Margin the price implies | Margin delivered | Position | PRCT | S&P 500 |
|---|---|---|---|---|---|---|
| September 30, 2026 (open) | $18.22 | 8.3% | -49.6% | Short | +6.7% | −0.8% |
| June 30, 2026 | $22.58 | 10.9% | -54.1% | Short | −19.3% | +2.4% |
| March 31, 2026 | $25.01 | 12.3% | -57.5% | Short | −9.7% | +15.1% |
| December 31, 2025 | $31.46 | 16.3% | -63.4% | Short | −20.5% | −4.4% |
| September 30, 2025 | $35.69 | 20.3% | -70.6% | Short | −11.8% | +2.7% |
| June 30, 2025 | $57.60 | 37.6% | -77.5% | Short | −38.0% | +8.1% |
| March 31, 2025 | $58.26 | 41.1% | -85.1% | Short | −1.1% | +10.8% |
| December 31, 2024 | $80.52 | 65.4% | -91.6% | Short | −27.6% | −4.3% |
| September 30, 2024 | $80.12 | 72.8% | -101.2% | Short | +0.5% | +2.5% |
| June 30, 2024 | $61.09 | 60.9% | -113.3% | Short | +31.1% | +5.8% |
| March 31, 2024 | $49.42 | 54.4% | -120.3% | Short | +23.6% | +4.4% |
| December 31, 2023 | $41.91 | 49.7% | -131.8% | Short | +17.9% | +10.4% |
| September 30, 2023 | $32.81 | 44.0% | -137.4% | Short | +27.7% | +11.6% |
| June 30, 2023 | $35.35 | 55.5% | -138.9% | Short | −7.2% | −3.2% |
| March 31, 2023 | $28.40 | 47.5% | -140.1% | Short | +24.5% | +8.7% |
What return on equity is the price paying for?
The price implies a return on equity of 20.8%; the company earned -30.2%.
Market more optimistic than our model: short this quarter
Over time
$10,000 trading the gap vs the S&P 500
Skill or luck?
In plain English: Across 14 quarters with a position, this lens beat the S&P 500 in 9, by +5.8% a quarter on average. That could easily be chance. One company is a small sample: the results across all companies are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 0 | — | — | — | — | — | — |
| Shorts | 14 | 64.3% | +5.8% | +7.9% | +16.4% | 1.05 | No reliable evidence |
| All positions | 14 | 64.3% | +5.8% | +7.9% | +16.4% | 1.05 | No reliable evidence |
Every quarter (15)
| From | Price paid | Return on equity the price implies | Return on equity delivered | Position | PRCT | S&P 500 |
|---|---|---|---|---|---|---|
| September 30, 2026 (open) | $18.22 | 20.8% | -30.2% | Short | +6.7% | −0.8% |
| June 30, 2026 | $22.58 | 24.5% | -27.8% | Short | −19.3% | +2.4% |
| March 31, 2026 | $25.01 | 25.5% | -24.9% | Short | −9.7% | +15.1% |
| December 31, 2025 | $31.46 | 30.2% | -27.2% | Short | −20.5% | −4.4% |
| September 30, 2025 | $35.69 | 33.3% | -26.4% | Short | −11.8% | +2.7% |
| June 30, 2025 | $57.60 | 51.3% | -27.6% | Short | −38.0% | +8.1% |
| March 31, 2025 | $58.26 | 49.3% | -26.8% | Short | −1.1% | +10.8% |
| December 31, 2024 | $80.52 | 106.7% | -37.0% | Short | −27.6% | −4.3% |
| September 30, 2024 | $80.12 | 101.1% | -50.9% | Short | +0.5% | +2.5% |
| June 30, 2024 | $61.09 | 73.3% | -47.3% | Short | +31.1% | +5.8% |
| March 31, 2024 | $49.42 | 55.8% | -44.3% | Short | +23.6% | +4.4% |
| December 31, 2023 | $41.91 | 43.1% | -41.0% | Short | +17.9% | +10.4% |
| September 30, 2023 | $32.81 | 59.5% | -52.9% | Short | +27.7% | +11.6% |
| June 30, 2023 | $35.35 | 57.7% | -46.2% | Short | −7.2% | −3.2% |
| March 31, 2023 | $28.40 | 41.2% | -37.5% | Short | +24.5% | +8.7% |
How the test works
At each quarter end since March 2010 we rebuild the models from Procept Biorobotics Corp's quarters ending at least 90 days earlier (and no more than 200 days before that), using the figures as later filed, including any restatement, and value them at that day's close, adjusted for later share splits and spin-offs so that price and share count are on the same basis. A wide enough gap is a long or a short for one quarter (growth 10 points; margin and return on equity 5 points; a PEG under 0.75 or over 3), measured on total return against the S&P 500. The rules were set before the test. No trading or borrowing costs; today's list of companies. Not investment advice. All companies and the results across them.
Compare with peers
- Staar Surgical Co priced in
- Angiodynamics Inc priced in
- Inogen Inc priced in
- Tactile Systems Technology Inc priced in
- Inmode Ltd. priced in
Head to head: PRCT vs STAAANGO vs PRCTINGN vs PRCT
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies